Latest Breaking News On - Craig hopkinson - Page 1 : comparemela.com

Alkermes to Present Data for ALKS 2680 in Narcolepsy Treatment

Alkermes will present new data for its investigational narcolepsy treatment, ALKS 2680, at SLEEP 2024 in Houston.

Alkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -

Alkermes plc: Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials

The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.

Alkermes plc: Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1